



A N N U A L R E P O R T 2 0 0 3



To give people **hope** and **relief** from
Multiple Sclerosis, we first must
map the **causes** which will lead to the **cure**.





Dear Boston Cure Project Supporters,

The end of 2003 marks the completion of our second full calendar year since our beginning in August of 2001. Back then, my co-founder Dr. Tim Vartanian and I came up with a vision to create an organization dedicated to curing Multiple Sclerosis by determining its causes. Two and a half years later that vision is becoming reality.

When I was diagnosed with MS in June of 2000, my life changed forever. Within six months I had decided to quit my job and dedicate myself full-time to do something about this disease. Through lots of reading, meetings, and numerous discussions with my neurologist, Dr. Tim Vartanian, he and I came up with the concept of the Boston Cure Project for Multiple Sclerosis. We would map out the research that needs to happen to determine the causes of MS, and do what needed to be done to make that research happen.

In this report you'll read about our progress on this mission over the past year — notably our progress on the Cure Map and the design and approval of our Pilot study to create a large-scale, multidisciplinary, blood, tissue, and data bank which will begin collecting samples at the Beth Israel Deaconess Medical Center in Boston in early 2004.

In addition, we'll tell you about our growth to four full-time staff members, additions to our Board of Directors and Scientific Advisory Board, our volunteer staff and interns, and our fundraising efforts that allowed us to exceed our goal of \$500,000 by more than 20%.

I'd like to thank all of our contributors, volunteers, staff, and advisors for the support, help, work, and money that has made our progress possible. We depend almost entirely on the support of individuals and couldn't have done all that we have without your help. Thank you very much!

Should you have any questions about the contents of this report or Boston Cure Project in general, please call me at 781-788-0880 or email me at art@bostoncure.org.

Regards,

Art Mellor
President & CEO Boston Cure Project, Inc.

PS: Our Annual Report is professionally designed and produced, but thanks to Clockwork Design Group, Frank Siteman Photography, Kirkwood Printing, RIS Paper Co., Mail Perfect, and our volunteers, it was produced and distributed significantly below cost.

“When I was diagnosed with MS in June of 2000, my **life** changed forever. My co-founder Dr. Tim Vartanian and I came up with a **vision** to **create** an organization dedicated to curing Multiple Sclerosis by determining its causes. Two and half years later that vision is **becoming reality.**”

— Art Mellor
President & CEO Boston Cure Project, Inc.

Mission

The Boston Cure Project for Multiple Sclerosis is a national nonprofit organization dedicated to curing Multiple Sclerosis by determining its causes. The Boston Cure Project believes this effort can be accelerated by organizing the research process and encouraging collaboration between research organizations and clinicians. We are developing a “Cure Map” to establish and document what is known and what is not known about the causes of Multiple Sclerosis. From the Cure Map, Boston Cure Project will facilitate research most likely to reveal the causes of MS in the shortest time through a large-scale, multidisciplinary, blood, tissue, and data bank.

Multiple Sclerosis

Multiple Sclerosis, or MS, is a chronic demyelinating disorder of the central nervous system affecting over 400,000 people in the US and 2 million individuals worldwide. MS often results in severe disability including the inability to walk, impaired vision or, in some cases, blindness, cognitive dysfunction, bladder and bowel problems, extreme fatigue and other serious side effects. MS impacts not only the persons with the disease, but their families as well. Unfortunately, no one knows what causes MS, there is no known cure for the disease, and available treatments are modestly effective at best.

Contents

President’s Letter	:	2
Mission	:	3
Volunteers & Contributors	:	3
Cure Map	:	4
Tissue Bank	:	5
Education & Community	:	7
Families with MS	:	9
Fundraising	:	9
Operations	:	10
Next Year	:	11
Financials	:	12

Volunteers and Contributions

Every contributor is important to us and we strive to credit you correctly. If we have incorrectly attributed your contribution, misspelled your name, or left you off the list by mistake, please contact us and let us know so we can correct this error in our records and on the web.

VOLUNTEERS:

- Shari Agatstein
- Janice Altman
- Stephanie Andrews
- Annemarie Armstrong
- Amanda Arter
- Savannah Bashaw
- Jay Batson
- Judy Batson
- Michelle Bernson
- Briezy Bessell
- Josh Binder
- Tom Blackadar
- Wendy Booker
- Steve Bowler
- Bob Brown
- Gordon Brownlee
- Larry Buckley
- Nancy Burstein
- Diane Butt
- Diane Carrara
- Marion Carroll
- Jeannie Connerney
- John Copeland
- Molly Corbett
- Jim & Sandy Delgaizo
- Brian Del Vecchio
- Jeffy Demeter
- Lisa Desautels
- Kip Diggs
- Keff Dolan
- Michelle Dolan
- Brian Donager
- Rob Donaldson
- Margaret Doris-Pierce
- Jen Downing
- Robert Drake
- John Dunphy
- Debbie Dutton
- Mary Dyer
- Mike Ervolini
- David Flannery
- Ellen Frank
- Joy Franks
- Debbie Frattaroli
- Pearl Freier
- Amanda Gaffey
- Julie Gershon
- Rose Gershon
- Bryan & Nancy Gildenberg
- Pasquale Giovanni

Cure Map

The Cure Map is the Boston Cure Project’s plan to determine the causes of Multiple Sclerosis. We know that like all other human diseases, MS is caused by one or more factors in five categories — genetics, pathogens, toxic agents, nutrition, and trauma — but we don’t yet know what these factors are. By systematically analyzing the results of past research into the causes of MS, prioritizing the unanswered questions, and designing and executing experiments to provide conclusive answers, we hope to find the causes of MS as efficiently and effectively as possible.

To create the Cure Map, we are addressing each of the five categories, or tracks, individually through a four-phase approach: In Phase 1 we are documenting what we know in general about that type of disease cause, not related to MS specifically, because we want to make sure to include ideas not yet examined in MS. Phase 2 consists of a comprehensive review of the scientific literature as it relates to MS, based on our generic analysis in Phase 1, to determine what we know and what we don’t know about how that cause may be involved in MS. In Phase 3 we will decide what open questions are most important to answer first, and come up with experiments to generate the necessary data. Finally, in Phase 4 we will find ways to implement those experiments.

Cure Map

	GENETICS	PATHOGENS	NUTRITION	TOXINS	TRAUMA
Phase 1	COMPLETE	COMPLETE	In Progress	In Progress	Pending
Phase 2	COMPLETE	In Progress			
Phase 3	In Progress	Pending			
Phase 4	In Progress: Blood and Tissue Bank				

Tissue and Data Bank

TWO REQUIREMENTS FOR SOLVING THIS COMPLEX MEDICAL MYSTERY

1. MS is a complex (multifactorial) disease— therefore we need to aggregate data across causes

AGGREGATED DATA

Genetics Pathogens Nutrition Toxins Trauma

2. MS may even be a group of diseases— therefore we need to collect and analyze information on large numbers of subjects


THE BOSTON CURE PROJECT TISSUE AND DATA BANK ADDRESSES BOTH REQUIREMENTS

Scientists working in different areas can pool their results to find important patterns and correlations if they study the same population.



Results and data are maintained on sufficient numbers of subjects to permit finding meaningful similarities

OPERATION OF THE BOSTON CURE PROJECT TISSUE AND DATA BANK



To develop the Cure Map, we had initially intended to take a breadth-first approach by concentrating on all the Phase 1 documents first. As we proceeded, we decided that doing the first two Phases in each track would lead us to actionable results more quickly. This year, we refocused our efforts to work on the Genetics Phase 2 portion of the Map. Our VP of Scientific Operations, Hollie Schmidt, reviewed thousands of scientific abstracts and read hundreds of papers on research into the genetic origins of MS. She distilled the results of those papers, wrote them up, and had them reviewed by members of our Scientific Advisory Board. The complete series of Genetics Phase 2 documents is available on our web site in the Downloads section along with the previously completed Genetics Phase 1 and Pathogens Phase 1 documents, and a detailed overview of the Cure Map strategy.

In addition, Hollie compiled a spreadsheet with a comprehensive list of the candidate gene and genome-wide screen studies performed in MS — a resource that did not exist anywhere before. Her work has prompted offers to collaborate on papers from MS genetics researchers at the Centers for Disease Control and Prevention and Duke University.

This year, the Boston Cure Project also entered into a collaboration with Entelos, a California-based company that specializes in biological computer models of disease. We have agreed to enlist pharmaceutical companies to join a consortium to create an “in-silico” (computer) model of MS. Entelos has agreed to develop the model for the consortium at cost, in exchange for ownership of the model as a future revenue-generating product. We believe that computer modeling will be an important

technology for MS research, as it helps organize the complex knowledge we have about MS and allows scientists to ask questions and get answers about the disease extremely quickly. Building an MS disease model will shorten drug development time, improve clinical trial design, and increase our understanding of how MS works.

Tissue Bank

Multiple Sclerosis has two characteristics that make it difficult to address via the traditional scientific and medical approaches. First, it appears to be a multifactorial disease, involving more than one root cause simultaneously (e.g. a genetic susceptibility and an environmental trigger). Second, it is most likely to be not a single disease, but rather a family of diseases with a common endpoint — each with its own differing set of root causes.

The first characteristic implies that researchers exploring different possible causes of MS must be able to study a common group of subjects so that their results can be pooled to detect combinations of causal factors that lead to developing MS. Because most research today is done in a single discipline on a unique set of subjects, combining data sets from different studies is difficult to do in a useful way. Even when researchers in one discipline are willing to share their samples and data, their resources are usually not appropriate for someone working in a different discipline.

The second characteristic implies that studies on people with “Multiple Sclerosis” may actually involve groups of

Maria Gjonaj
 Glen Glater
 Rachel Golub
 Betsy Gonnerman
 Melody Gonzalez
 Audrey Gordon
 Jill Graynor
 Mark Halliday
 Brian Hamilton
 Janelle Hamilton
 Chris Harding
 Billy Harless
 Maggie Harling
 Peter Harris
 Adam Hayes
 Sue Heilman
 Noreen Henson
 Bill Herron
 Johnny Higgins
 David Hirschberg
 Lori Holloran
 Carmen Hsieh
 A.P. Hurd
 Emeka Iffih
 David Isenberg
 Rosalind Joffe
 Marty Joyce
 Bernadette Kalman
 Arthur & Phyllis Kaplan
 Nancy Kaplan
 Leslie Kenney
 Laura Kesser
 Randi Kestin
 Jeff Kim
 Cynthia King
 Jan Klein
 Ken Kuperstein
 Cynthia Labow
 Kim Labow
 Patrice LaFont
 Marcie Lascher
 Michael Leite
 Paul Lynch
 Jaime Lysik
 Kimberly Lytle
 Alyssa Mades
 David & Linda Mades
 Harvey & Ruth Mades
 Gary Magnant
 Bruce Manning
 Dan Marean
 Gail Martino
 Bernard Marton
 Frederick Marx
 Jacqueline McCoy
 Jill McGaffigan
 Kristina McHale
 Ashana Mellor
 Brian & Susan Mellor
 Debbie Mellor
 Wendy Menning
 Krista Milne
 Joanne Minassian



“It isn't the fear of the unknown as much as
losing what I know

and love today. With the efforts of the

Boston Cure Project, I believe the research

will have a **positive effect**

on the understanding of MS and that

I will be ok as a result.”

— **Jennifer Downing**
Sales Executive

people with a number of differing diseases. Therefore, a cause that only applies to a subset of people with MS may not be detected in a study that only includes tens or hundreds of subjects. Larger studies that analyze thousands of subjects are needed to provide sufficient statistical power to identify the subtypes of MS and their causes.

At the beginning of 2003 we developed the idea of creating a large-scale, multidisciplinary, blood, tissue, and data bank to address these issues. Our idea was to start a sample collection which would ultimately contain thousands of samples from people with MS and matched controls. The samples would be collected in a manner that would make them simultaneously useful to people in many disciplines. These samples would be collected along with medical records and epidemiological data and be made available to researchers looking into the causes of MS in areas highlighted as important by the Cure Map. In exchange for access to the samples, the researchers would be required to eventually deposit the data they generate into the data bank, so that future researchers could also access that data along with the samples.

We documented the idea and took it around the country to about 30 different MS researchers and public health professionals. The response was very positive and confirmed that a resource like this was greatly needed. Coincidentally, the NIH published a document entitled “National Institute of Health Autoimmune Diseases Coordinating Committee Autoimmune Diseases Research Plan” early in the year that spelled out an approach to autoimmune diseases that mirrored our concept.

Why hasn't such a bank been built already? It boils down to three main reasons: 1) It's expensive, more expensive than most research grants are willing to pay for. 2) It's administratively difficult. The coordination among many centers and clinics, the Institutional Review Board approvals, the design of questionnaires, etc., are time consuming and boring (and frankly, not science — which is what scientists want to do). 3) It isn't publishable. Creating the infrastructure alone is not publishable, something that is necessary if you are a researcher looking for funding.

It was clear that building this necessary infrastructure had to be done by an organization outside of the research community who was willing to work with the research community. We feel this was exactly in line with the Boston Cure Project mission.

It took longer than we anticipated, but over the course of the year we developed a study protocol, an informed consent

form, and an extensive thirty-page questionnaire. We signed a contract with our new partner Genomics Collaborative, a Cambridge, Massachusetts based company that will create the kits to collect the samples, receive, process and store the samples and data, and distribute it all at our direction. They have also provided significant help in the development of the protocol and informed consent form.

We are launching a pilot study to collect 100 samples to prove capability and to collect data on recruiting rates and cost structure so that we can more accurately plan a follow-on collection of 1000 samples. We predict this will take the better portion of the year to complete as we come up to speed on what needs to be done. We intend to follow up that collection with a 5,000- and then a 10,000-sample collection.

In the last days of December 2003, we were notified that our pilot study had been approved by the Institutional Review Board (IRB) at the Beth Israel Deaconess Medical Center in Boston. The IRB is the ethics committee responsible for approving all studies involving humans. All human research facilities are required to have an IRB. With this approval we may now enter into negotiations for the financial aspects of the collection with the hospital. We will also be approaching a second clinic to participate in the pilot, once the first is underway.

Education & Community Building

In addition to our primary programs, the Cure Map and the Tissue Bank, the Boston Cure Project also runs programs in Education and Community Building.

One of our main educational efforts is our MSNews web site at msnews.bostoncure.org which features daily updates on news related to Multiple Sclerosis. We scour the news, scientific journals, and related web sites to bring together a collection of the most pertinent stories related to MS. These include new research breakthroughs, pharmaceutical company updates, events, news on people with MS, and many other topics. These stories are made available at the MSNews web site, which can be accessed at no charge. Users who choose to register (also at no charge) can receive updates daily via email. Comments can be posted on each story on the site, allowing for discussion among the readers.

We held one class this year titled, “The Genetic Basis of MS: What we know and what we don’t know about how genes cause MS,” covering our work on Genetics Phases 1 and 2 of the Cure Map. The details for the class and slides from it are available at our web site in the Events section.

Volunteer Rosalind Joffe wrote a paper entitled “7 Habits For Regaining Power in the Workplace With Chronic Illness,” which is available in the MS Resources section of our web site. Hollie has launched a series of interviews with MS researchers, and two of these are also currently available in this section — one with UCSF MS Geneticist Jorge Oksenberg and one with NIH MS Viral Immunologist Steven Jacobson.

Almost completed is our brochure for the newly diagnosed, a project we have been working on all year with Lisa Paine, Maggie Harling, and Cynthia King. This document is a “quick start” guide for getting up to speed on MS for people who have recently been diagnosed and their families. We’ll make this available on our web site and in neurologists’ offices as soon as it has been finalized.

Mark Minassian
Sara Mortenson
Maryann Boyle Murray
Charlie Namias
Carl Nickerson
Mary Ann Nordwall
David Olson
Kari Olson
Anthony O’Shea
Kim Pagan
Lisa Paine
Ernest Parizeau
Anna Peabody
Katie Peabody
Ezra Peisach
Greg Pelosi
Jane Pickett
Linda Pirie
Justin Polanik
Chuck Potier
Sujit Purkayastha
Ed Raws
Dave Ray
Fiona Reardon
Anne Reed
Nikki Rivera
Amanda Rossi
Erika Sanders
Jazmin Santiago
Lisa Sargeant
Peter Schmidt
David Schreiber
Andy Shein
Rachel Sheinbein
Joel Shore
David Shute
Michael Silton
David Simon
Stephanie & Frank Sisto
Hillary Stanton
Tom Stephens
Ru Sweeney
Mark Tavitian
Laurie Teifeld
Suresh Tipirneni
Bobby Trieger
John Ulfland
Belinda Vandervoort
Peter Vass
Stan Vernon
Lynn Vesey
Ken & Amanda Viciana
Janine Wanee
Ralph & Freda Warrington
Alan Weinberg
Debby Wiesen
Jen Wise
Matt Wise
Orania Wolf
Kevin Wood
Wilbur Wood
Graham Wright



We continue to keep our constituency up to date on our progress through our email mailing lists (now over 1,000 strong) and our quarterly print newsletter (going to almost 3,000 people). You can sign up to receive these lists in the Sign Up section of our web site. We also post all documents we develop and list all upcoming and past events at our web site, which got a major redesign this year, thanks to Deb Brown, Theresa Hahn, and Chad Tempest.

We received quite a bit of press this year: We were in the Boston Globe four times (three with photos), BioIT World two times, numerous local publications and web portals, and got our first national press with a 5 page spread in Fortune Small Business. Art authored a chapter in the book "People with MS with the Courage to Give" by Jackie Waldman, which was published last summer. The Public Service Announcement that Robotham Creative developed for us last year was completed, distributed, and aired, and we also got listed at the NIH web site as an MS organization, which has driven a lot of traffic to our site.

We make an effort to get out often to meet with people affected by MS. We attend many of the talks sponsored by the pharmaceutical companies and other MS organizations, and this year for the first time we hosted a table at a Teva event.

In 2003 we began a series of MS Socials to provide a venue for people with MS and their families and friends to get together and meet others in an informal setting. These events provide a means for people to get to know each other socially rather than in a lecture or support group situation.

We also try to make contact with as many MS researchers, clinicians, and pharmaceutical companies as we can. To this end we have greatly enhanced our Scientific and Pharmaceutical Advisory Boards, as you will note later in this report. We attended the American Academy of Neurology annual meeting where we met many of the top MS researchers and heard them present their latest findings.

We meet with many other similar organizations to ours, especially those working in the MS area, but also some in different areas that we think we can learn from. Just this year we have been in contact with the NIH, CDC, Myelin Repair Foundation, Multiple Sclerosis Foundation, National MS Society, Montel Williams Foundation, Race to Erase MS, AWARES, and Core Connections. We have also visited numerous MS clinics around the country.

"My diagnosis helped me develop and reprioritize both personal and professional goals. One of these goals was to form a support group for newly diagnosed individuals. Done. Another is to help find a cure for this disease. Boston Cure Project's mission is impressive and clearly in sync with this goal."

— Alan Weinberg
President & CEO Aljan Multimedia

Outside of the MS arena we have been in touch with the Autism Brainbank, National Organization for Rare Diseases, Progeria Research Foundation, ALS-TDF, Alzforum.org, Cystic Fibrosis Foundation Therapeutics, Christopher Reeve Paralysis Foundation, Epilepsy Cure Project, Horizons Initiative, Michael J. Fox Foundation, and others. We trade information on our approaches to research, fundraising, and outreach with them as a means of learning and sharing what we have learned.

Families with MS

In 2001, Boston Cure Project director George Peabody's daughter Anna was diagnosed with MS at the age of 15. Pediatric MS is rare (estimated at only 5% of MS cases) and it was a year and a half before the Peabodys encountered another family in the same situation. It was a very difficult experience to have to go through alone.

In order to provide support for other families who have children diagnosed with MS, George started a new program at the Boston Cure Project called "Families With MS." Parents of children with MS can sign up to get in touch with other families affected by MS. In addition, George and his sister have begun creating a documentary called "Finding Our Way" that chronicles the stories and advice of others affected by pediatric MS or working in the area professionally.

You can learn more about this program at www.familieswithms.org.

Fundraising

In 2003 we raised \$625,000 in cash and \$67,000 as in-kind gifts and services. These contributions came from over 1100 contributors.

The biggest change in fundraising this year was our addition of a full-time Development Manager who began the year with us as Melissa Baker and ended the year with us as Melissa O'Shea, having got married in August. Adding Melissa has allowed us to significantly increase our capacity.

In addition to our two traditional events — the Scavenger Hunt run by Lisa Sargeant, and the Annual Boston Cure Party with guests of honor Dr. Gerald Fischbach, former head of NINDS, and Dr. Michael Racke of UTSW — we held four other fundraising events: We had a Cut-a-Thon in Virginia, thanks to volunteer Janelle Hamilton of About Face Hair Design. We held a \$20,000 Anna Peabody Fund raffle, thanks to now director Charlie Namias and the Peabody/Kaplan family. We had our first golf tournament, thanks to Hank Tuohy, and held a classical music concert, thanks to volunteer Marion Leeds Carroll. Details and pictures for all these events are available in the Events section of our web site.

We conducted two written appeals, received our first formal grant from the Fleet Perpetual Trust for Charitable Giving/Henry Reed Fund for \$30,000, set up the necessary procedures to take vehicle donations, and met the Watercove Charitable Foundation \$50,000 matching challenge that matched contributions from individuals which were above and beyond what they gave last year.

Volunteer Run Events

- Juggle-a-thon—Bridgewater Men's College Soccer Team led by K. Brendan Adams
- "Sing to Cure MS" Halloween Concert—Marion Leeds Carroll
- "Cuts for A Cure" Cut-a-thon—Janelle Hamilton
- The Anna Peabody Fund Raffle—Peabody/Kaplan Family and Charlie Namias
- Edmond J. Medeiros Foundation Event—Nancy and Judy Medeiros
- Sense of Purpose program—Sponsored by Fitsense
- Participants:
 - Father Bernard Marton
 - Tal Viskin
 - David Agatstein
 - Michael Frech
 - Keith and Lauren Bregman
- Donated cost of wedding favors to Michael Frech's Sense of Purpose campaign
- Just Books, Inc. MS Days—Jenny Lawton, Owner
- Appeal Letters
 - David Blohm
 - Fred Marx
 - Jacqueline McCoy
 - Krista Milne
 - Belinda Vandervoort
- Halloween Parties—Nancy Costello and Karla Nelson
- Bike Ride—Jay and Judy Batson

Companies that matched their employee's contributions:

- Barclay's Global Investors
- Deutsche Bank Americas
- Fleet
- Juniper
- Merrill Lynch & Co.
- Microsoft
- PepsiCo
- Starbucks
- Sun Microsystems
- Wellington Management Company, LLP



“Living with MS for fourteen years has taught me far more than it has taken away.

The best part? Crossing paths with extraordinary people. The tireless **diligence** of the Boston Cure Project has restored my **hope**

the cause of this disease will be realized and a **cure** will eventually emerge.”

— Lisa Desautels
Writer/Lecturer

We had significant volunteer fundraising efforts in addition to our events: We launched the Sense of Purpose running program in conjunction with Fittsense, a maker of running and fitness equipment. Through this program, runners raise money to support the Boston Cure Project when running in otherwise unsponsored races. We had quite a few volunteers conduct letter-writing campaigns to their friends and families, which brought in significant contributions and many new people for the mailing list.

Last year, the Peabody/Kaplan family started a named fund to benefit the Boston Cure Project called the Anna Peabody Fund, in honor of their daughter Anna. Through the tremendous efforts of their family, notably George, Katie, and Anna Peabody and Nancy, Arthur, and Phyllis Kaplan, the fund raised \$118,000 in 2003 and was our most successful fundraising program. Using their efforts as a template, we hope to launch several new named funds in 2004.

Operations

The Boston Cure Project's operations ran quite uneventfully this year, thanks to our Operations Manager Andrea Briggs, and our volunteer administrative assistant Sue Mellor. They have been responsible for all the activities of the company that are not directly mission related, including day-to-day bookkeeping, data entry and updating, mailings, human resources, facilities, and the production of our quarterly print newsletter.

We get significant financial and accounting help from advisors Mike Gonnerman, Jill McGaffigan, Debbie Frattaroli, and Jacqui McCoy. On the computer system and web administration side we get help from volunteers Brian Del Vecchio, Bill Babcock, Theresa Hahn, and Chad Tempest.

In addition, we had 190 volunteers provide 4100 hours of volunteer time on over 50 projects. This help eliminates the need to hire people to do the work and considerably reduces our expenses.

Next Year

Our main goals for the coming year, 2004, are straightforward:

For the Blood, Tissue, and Data Bank

- **Complete the pilot trial collection of 100 samples**
- **Distribute the samples and data to at least one research project**
- **Design and begin the approval process for follow-on collection of 1000 samples**

In addition, we will continue work on the Cure Map, focusing on the Pathogens Phase 2 work, and our Education and Community Building efforts including Families With MS. We are budgeting \$750,000 to continue our efforts in 2004.



“Our **daughter** Anna has had MS for three years. She’s **just 18**. This is all about finding the causes so she can **look forward** to a cure. The Boston Cure Project is the best path I can take to speed that goal. I am **proud** to be part of it.”

— **George Peabody**
Board of Directors

CONTRIBUTIONS:

Every contributor is important to us and we strive to credit you correctly. If we have incorrectly attributed your contribution, misspelled your name, or left you off this list by mistake, please contact us and let us know so we can correct this error in our records.

Due to space limitations and the large number of contributions, we are unable to credit those people making contributions under \$250 in this report.

\$100,000 AND ABOVE

Watercove Charitable Foundation

\$50,000 AND ABOVE

Anonymous (2)

Tidewater Jewish Foundation

\$25,000 AND ABOVE

Biogen, Inc.

Perpetual Trust for Charitable Giving/Henry Reed Fund

\$10,000 AND ABOVE

Art & Debbie Mellor

Severino Gift Fund

Stephen & Leigh Vartanian

Steven Willis

\$5,000 AND ABOVE

Alex & Brit d'Arbeloff

Heather Humphrey

Brad & Jennifer Parker

Grigsby C. Peabody

Serono Inc.

Frank & Emilie Slaughter Found

Teva Neuroscience, Inc.

The Viyu Foundation

\$1000 AND ABOVE

Ian Agranat

Anonymous (2)

Atlas Venture

Baltimore Community Foundation

Charles & Christina Bascom

Keith & Lauren Bregman

Marc Cohen

Comm Health Charities

Andrea Briggs & John Copeland

Edward Doyle

P & J Egerman Family Charitable Foundation in honor of David Blohm

Entelos


Feeley & Driscoll

Fueldog, Inc.


Mark & Jan Godat

Financials 2003


CONTRIBUTIONS BY SIZE



EXPENSES BY PROGRAM



EXPENSES BY CATEGORY



HIGHLIGHTS

- Received \$624,000 of cash contributions from 1,877 donors, up from \$253,000 in 2002 (a 147% improvement). In 2003, 7 donors accounted for 47% of our contributions.
- Received \$67,000 of donated services.
- The cash contributions include \$14,000 received during 2003 that remain restricted at December 31, 2003, and will be expended during 2004.
- Ended the year with \$186,000 in cash.
- Spent 37% on program activities. We expect this ratio to increase significantly during 2004 as our revenues increase and we roll out the Tissue Bank project.
- Worked with the firm of Hemenway & Barnes, our legal counsel, and Feeley & Driscoll, P.C., our auditors.
- Invested \$98,000 in developing the Cure Map for multiple sclerosis. This project is fundamental to our efforts because it identifies the areas that need to be investigated. You can see the documented results at our web site, www.bostoncure.org.
- Invested \$74,000 in the Community Building project, which brings people with MS together and makes them aware of what is happening in the MS community.
- Kept spending on administrative areas to a minimum by paying below-market rates.

Note — the accompanying financial information is unaudited. You may request the audited financial statements, which will be available in May 2004.

STATEMENT OF FINANCIAL POSITION

As of December 31, 2003 and 2002
Unaudited

	2003	2002
ASSETS		
Current Assets		
Cash	\$185,877	\$27,319
Contributions Receivable	12,370	3,281
Prepaid Expenses and Other Current Assets	8,344	8,662
	206,591	39,262
Property and Equipment		
Equipment	3,811	3,811
Less — Accumulated Depreciation	-3,017	-1,747
	794	2,064
	<u>\$207,385</u>	<u>\$41,326</u>
LIABILITIES AND NET ASSETS		
Current Liabilities		
Accounts Payable	\$5,264	\$2,008
Accrued Expenses	9,285	23,735
	14,549	25,743
Net Assets		
Unrestricted	178,939	15,583
Temporarily Restricted	13,897	0
	192,836	15,583
	<u>\$207,385</u>	<u>\$41,326</u>

Mike & Betsy Gonnerman
Joe Graham
Sarah E. Helm
Mark Hilbert
Jeff & Georgie Hotchkiss
Emily Jones
Dr. & Mrs. Arthur Kaplan
John Krawczyk
Frederic J. Marx
Mark Aher & Jacqueline McCoy
Brian & Susan Mellor
Charles & Deborah Namias
Melissa & Anthony O'Shea in
honor of Art Mellor and
Kay Lynch
Millennium Pharmaceuticals
Old Colony Sports
O'Sheas of Kerry Travel
John Kleshinski & Emily Paul
John & Fiona Reardon
Reinemund Family Foundation
Peggy Richardson
George & Rebekah Richardson
Robertson's GMC
Hollie & Peter Schmidt
West Suburban Imaging Ctr
Bradley Whitford Family Trust
Kevin & Tracey Wood
Neal & Susan Yanofsky Family
Fund
The Yaspan Unterberg
Foundation

STATEMENT OF ACTIVITIES

For the Two Years Ended December 31, 2003
Unaudited

	2003			2002
	Unrestricted	Temporarily Restricted	Total	Total
Operating revenues				
Contribution revenues	\$629,795	\$61,334	\$691,129	\$294,716
Net assets released from restrictions	47,437	(47,437)	0	0
Total revenues	677,232	13,897	691,129	294,716
Operating expenses				
Program services				
Cure map program	98,458	0	98,458	113,438
Community building	73,770	0	73,770	47,670
Educaton	19,734	0	19,734	25,583
	191,962	0	191,962	186,691
Supporting services				
Fund raising	122,321	0	122,321	54,662
Management and general	200,150	0	200,150	97,852
	322,471	0	322,471	152,514
	514,433	0	514,433	339,205
Amount by which operating revenues are greater (less) than expenses	162,799	13,897	176,696	(44,489)
Realized gain (loss) on investments	557	0	557	(30)
Change in net assets	163,356	13,897	177,253	(44,519)
Net assets, beginning of period	15,583	0	15,583	60,102
Net assets, end of period	<u>\$178,939</u>	<u>\$13,897</u>	<u>\$192,836</u>	<u>\$15,583</u>

\$500 AND ABOVE

Kevin Agatstein
R. Byron & Laura Barker Carloc
Greg Chesko
Stuart Clarke
Nancy Costello
Adelbert Custodio
CVS Corporation
Robert Donaldson
Tony & Linda Falcone
M. Kathleen & Albert Frech
Mike & Katrina Geitner
Paul & Marianne Gertman
Brian Gildenberg
Go 2 Communications, Inc.
Kristin Greene
Eduard & Yvetta Guzovsky
Daniel & J. Elizabeth Hennessy
Jerry Hirschberg
Fiona Hodgson
Howard Kesser
Sarah Isenberg
Kathleen Kinnevy
The Mancini Foundation
Randall Kaplan & Kathy Manning
Jill McGaffigan
Nancy & Judy Medeiros in loving
memory of their brother,
Edmund J. Medeiros
Wendy Menning
MicroTek
Aram Minassian
Our Love Fund
Eric Tiffany & Lee Park

VENDORS:

We would like to thank our vendors for their services this past year.

Bank: Citizens Bank

**Bookkeeping:
Debbie Frattaroli**

**Credit Card Transactions:
Network for Good**

**Graphic Designers:
Clockwork Design Group**

**Legal:
Hemenway & Barnes**

**Mailing: Rich Macaluso
at Mail Perfect**

**Office Sublet:
Gold Wire Technology**

**Public Relations:
Krista Milne
at Mojo Marketing**

**Taxes & Auditors:
Feeley & Driscoll**

**Tissue and Data Storage:
Genomics Collaborative**

CREDITS:

We would like to thank those who contributed to this Annual Report at no charge or significantly reduced price:

**Design:
Clockwork Design Group
Woburn, MA, 781-938-0006
www.cdgi.com**

**Photography:
Frank Siteman
Photography
Winchester, MA, 781-729-3747
www.franksiteman.com**

**Printing:
Kirkwood Printing,
Wilmington, MA 978-658-4200**

**Paper:
RIS Paper Co.,
Mansfield, MA 800-344-1715
Creator Silk 80# Cover**

**Mailing: Mail Perfect Inc.
Shrewsbury, VT, 800-774-7110
www.mailperfect.com**

**Written by: Art Mellor &
Hollie Schmidt**

**Editors: Boston Cure
Project Staff, Carol Rose**



Gheorghe & Carol Radu
David Raffaele
Michael & Betty Rasmussen
Shari Agatstein & Mimir
Reynisson
Dwight Risky
Rothstein Foundation
Andrew M. Wallerstein & Mary
C. Sloane in Honor of
Frederic J. Marx
Ronald Starr
Sun Life Financial
Eric Tenenbaum
Gray Thoron in honor of Anne
Reed

\$250 AND ABOVE

American Express Financial
Advisors
Anonymous (2)
Bill & Jennifer Babcock
Maria Bell
Amy Bernstein
David Blohm
Steve & Helene Bowler
Michael Stoller & Wilma Brooks
C.S.I. Speciality Construction
Steve Carlson
Bruce & Phyllis Carr
Jeffrey Connor
Tracy Dart
Bertha Ann De Leon
Douglas DeAngelis
Lisa Desautels
Tarek & Amy Elkachouty
Bill Fanselow
Michael Feinstein
Five Star Quality Care, Inc.
Debbie Frattaroli
Lawrence J. Goldrich Foundation
Great American Wall Systems
Erik & Pirjo Heels
John Lechner IV & Mary Higgins
in Honor of Jacqui McCoy
Sondra Homer-Warner
Stephen & Patricia Johnston
Jennifer Kulm
Judith Langmaid
Marcie Lascher
James & Erin MacStravic
Virginia Mahoney
Bruce Manning
Daniel Marean
Michael Marquardt
MC Communications
Jeff McCarthy
Kevin & Lisa McGoff
National City Mortgage Company
Karla Nelson
Paul Michael Miller
Joanne Minassian
Michael & Susan Mitchell
Brad & Jennifer Parker
Sara Peabody
Charles Alan & Suzanne Peyser
Douglas & Geri Potter
Andrei & Cristina Radulescu-Banu

Stephen Krause & Jane Raffaele
Michael & Anne Reed
Anthony Riela
Barry Rosenblum
Barbara Sannwald
Jane & Angelo Santinelli Family
Fund
Lisa Sargeant
Tom Blackadar & Paula
Shakespeare
Braden Sparks
Sportsworld, Inc.
Alan & Bonnie Steele
Stephens Family Gift Fund
R. Gregg Stone in honor of
Frederic J. Marx
THG Sales Automatics
John Ulwick
Patrick McLaughlin &
Cynthia Yered

CONTRIBUTIONS OF GOODS & SERVICES:

\$25,000 AND ABOVE

Clockwork Design Group, Inc.

\$5,000 AND ABOVE

Mojo Marketing, Inc.
Orchestrated Media LLC

\$2,500 AND ABOVE

Landay & Leblang
Pride Printers, Inc.
Frank Siteman Photography

\$1,000 AND ABOVE

Fore Golfers Only
Biogen, Inc.

PERSONNEL

We have a small full-time staff, but a significant network of supporters, as you can see from the lists below. Most of these people have short biographies on our web site if you would like to learn more about them.

Staff:

President: Art Mellor
Vice President of Scientific
Operations: Hollie Schmidt
Development Manager:
Melissa O'Shea
Operations Manager:
Andrea Briggs

Volunteer Staff:

Administration: Sue Mellor
Events: Debbie Mellor
Scavenger Hunt: Lisa Sargeant

Board of Directors:

David Blohm—*President, Blohm
Group*
Jacqui McCoy—*Partner, Paul I
McCoy Family Office Services LLP*
Art Mellor—*President, Boston
Cure Project*
Charlie Namias—*President, Mass
Networks, Inc.*
George Peabody—*President,
Climbing Trees Coaching*
John Reardon—*Principal
Engineer, Gold Wire Technology,
Inc.*
Tim Vartanian, M.D., Ph.D.—*Chief
of the Division on Demyelinating
Diseases at the Beth Israel
Deaconess Medical Center*

Scientific Advisory Board:

John Copeland, Ph.D.—*Director
of Clinical Physics in the
Department of Radiology at the
Beth Israel Deaconess Medical
Center*
Allitia DiBernardo, M.D.—*Clinical
Fellow in Neurology at the
Massachusetts General Hospital
and Brigham and Women's
Hospital*
Marie Filbin, Ph.D.—*Distinguished Professor of Biology
at Hunter College*
Elliot Frohman, M.D., Ph.D.—*Associate Professor of Neurology
and Ophthalmology at the
University of Texas Southwestern
Medical Center*
Douglas Golenbock, M.D.—*Chief
of Infectious Diseases and
Immunology at the University of
Massachusetts Medical School*

Steven Jacobson, Ph.D.—*Chief of
the Viral Immunology Section in
the National Institute of
Neurological Disorders and Stroke
at the National Institutes of
Health*

Rip Kinkel, M.D.—*Director of the
Multiple Sclerosis Center at the
Beth Israel Deaconess Medical
Center*

Peter Lansbury, Ph.D.—*Director
of the Center for Neurologic
Diseases at the Brigham and
Women's Hospital*

Vince Macaluso, M.D.—*Staff
Physician at Flushing Hospital
Medical Center*

Jorge R. Oksenberg, Ph.D.—*Associate Professor in the
Department of Neurology,
University of California, San
Francisco*

Michael Racke, M.D.—*Vice
Chairman for Neurology Research
and Director of Neuroimmunology
Research at the University of
Texas Southwestern Medical
Center*

Raj Ratan, M.D., Ph.D.—*Director
of the Neuroprotection Laboratory
at Beth Israel Deaconess Medical
Center*

Peter Riskind, M.D., Ph.D.—*Associate Professor of Clinical
Neurology and Director of the
Multiple Sclerosis Clinic at the
University of Massachusetts
Medical School and UMass
Memorial Health Center*

Saud Sadiq, M.D.—*Director of the
MS Research and Treatment
Center at St. Luke's Roosevelt*

David Simon, M.D., Ph.D.—*Staff
Physician at the Beth Israel
Deaconess Medical Center and
Assistant Professor of neurology
at the Harvard Medical School*

Tim Vartanian, M.D., Ph.D.—*Chief
of the Division on Demyelinating
Diseases at the Beth Israel
Deaconess Medical Center*

Pharmaceutical Advisory Board:

Ayad Abdul-Ahad, M.B., Ch.B.,
M.Sc., Ph.D., FRCPATH — *Vice
President of CNS Clinical
Development at Berlex
Laboratories Inc.*
John Alam, M.D.—*Vice President
of Drug Evaluation and Approval
at Vertex Pharmaceuticals*
Alfred W. Sandrock, Jr., M.D.,
Ph.D.—*Senior Director of Clinical
Development in Neurology at
Biogen, Inc.*
Nancy Simonian, M.D.—*Vice
President of Clinical Development
at Millennium Pharmaceuticals,
Inc.*
Fredric Vinick, Ph.D.—*Vice
President, Drug Discovery at
Genzyme Corporation*
David Weinstein, M.D.—*Vice
President and Chief Scientific
Officer at GliaMed, Inc.*

Board of Advisors:

Mike Ervolini—*CEO of Winthrop
Analytics Corporation*
Mike Gonnerman—*CEO of
Michael Gonnerman, Inc.*
Eric D. Hovde—*President and
CEO of Hovde Capital Advisors*
Frederic J. Marx—*Partner at the
law firm of Hemenway & Barnes*
Jill McGaffigan—*Director of
Operations and Controller of Gold
Wire Technology*

Interns:

Peter Harris, Noble &
Greenough High School
Stephanie Sisto, Simmons
College
Hillary Stanton, MIT
MIT Sloan Tiger Team 1
• Michelle Bernson
• Josh Binder
• A-P Hurd
• Sara Mortenson
• Rachel Sheinbein
MIT Sloan Tiger Team 2
• John Capello
• Emeka Iffih
• Jeff Kim

Appeal

The Boston Cure Project is primarily supported by contributions from individuals. We spend every dollar we receive supporting our programs—so a gift of any amount is immediately applied to our work of curing Multiple Sclerosis by determining the causes.

Contributions can be made by check, credit card, stock, vehicle donation, or in-kind gift. We are a 501(c)3 nonprofit so your contribution may be tax-deductible. Detailed information on giving is available at www.bostoncure.org.

Please make checks payable to:

Boston Cure Project, Inc.

13 Belton Street

Arlington, MA 02474

781-788-0880

info@bostoncure.org

Tax ID: 04-3555864

You can request a contribution envelope by calling the number above or by sending an email to the address listed above. Credit card contributions can be made online at www.bostoncure.org in the Contribute section.

You can sign up to receive periodic email updates, notices about volunteer opportunities, and our quarterly printed newsletter at www.bostoncure.org in the Sign Up section.

